Faizi A Jamal1, Samer K Khaled2. 1. Division of Cardiology, Department of Medicine, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA, 91010, USA. fjamal@coh.org. 2. Department of Hematology, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA, 91010, USA.
Abstract
PURPOSE OF REVIEW: Chimeric antigen receptor T cell therapy is gaining clinical use in the management of B cell lymphomas. As the use of this unique treatment option increases, its associated toxicities will require recognition and treatment. In this review, we aim to discuss the cardiovascular toxicities of chimeric antigen receptor T cell therapy and our approach to their clinical management. RECENT FINDINGS: Cardiotoxicity may be due to direct or indirect effects of infused chimeric antigen receptor T cells. The cytokine release syndrome has been described extensively in the literature. Studies have also reported cardiovascular dysfunction including hypotension, left ventricular dysfunction, heart failure, and cardiogenic shock in the setting of cytokine release syndrome. While there are no standardized guidelines for the treatment of cytokine release syndrome or associated cardiotoxicity, we present our current clinical practices. Further research is indicated into the pathophysiology of therapy-associated cardiac dysfunction and effective management strategies to optimize patient outcomes.
PURPOSE OF REVIEW: Chimeric antigen receptor T cell therapy is gaining clinical use in the management of B cell lymphomas. As the use of this unique treatment option increases, its associated toxicities will require recognition and treatment. In this review, we aim to discuss the cardiovascular toxicities of chimeric antigen receptor T cell therapy and our approach to their clinical management. RECENT FINDINGS:Cardiotoxicity may be due to direct or indirect effects of infused chimeric antigen receptor T cells. The cytokine release syndrome has been described extensively in the literature. Studies have also reported cardiovascular dysfunction including hypotension, left ventricular dysfunction, heart failure, and cardiogenic shock in the setting of cytokine release syndrome. While there are no standardized guidelines for the treatment of cytokine release syndrome or associated cardiotoxicity, we present our current clinical practices. Further research is indicated into the pathophysiology of therapy-associated cardiac dysfunction and effective management strategies to optimize patient outcomes.
Authors: Tomasz J Guzik; Saidi A Mohiddin; Anthony Dimarco; Vimal Patel; Kostas Savvatis; Federica M Marelli-Berg; Meena S Madhur; Maciej Tomaszewski; Pasquale Maffia; Fulvio D'Acquisto; Stuart A Nicklin; Ali J Marian; Ryszard Nosalski; Eleanor C Murray; Bartlomiej Guzik; Colin Berry; Rhian M Touyz; Reinhold Kreutz; Dao Wen Wang; David Bhella; Orlando Sagliocco; Filippo Crea; Emma C Thomson; Iain B McInnes Journal: Cardiovasc Res Date: 2020-08-01 Impact factor: 10.787
Authors: Eduardo Gutiérrez-Abejón; Francisco Herrera-Gómez; Débora Martín-García; Eduardo Tamayo; Francisco Javier Álvarez Journal: J Cardiovasc Dev Dis Date: 2021-11-29
Authors: Rudolf A de Boer; Joseph Pierre Aboumsallem; Valentina Bracun; Douglas Leedy; Richard Cheng; Sahishnu Patel; David Rayan; Svetlana Zaharova; Jennifer Rymer; Jennifer M Kwan; Joshua Levenson; Claudio Ronco; Paaladinesh Thavendiranathan; Sherry-Ann Brown Journal: Cardiooncology Date: 2021-06-21
Authors: John E Levine; Stephan A Grupp; Michael A Pulsipher; Andrew C Dietz; Susana Rives; G Douglas Myers; Keith J August; Michael R Verneris; Jochen Buechner; Theodore W Laetsch; Henrique Bittencourt; Andre Baruchel; Michael W Boyer; Barbara De Moerloose; Muna Qayed; Stella M Davies; Christine L Phillips; Timothy A Driscoll; Peter Bader; Krysta Schlis; Patricia A Wood; Rajen Mody; Lan Yi; Mimi Leung; Lamis K Eldjerou; Carl H June; Shannon L Maude Journal: J Immunother Cancer Date: 2021-08 Impact factor: 13.751